54 related articles for article (PubMed ID: 30833420)
1. Epigenetic Regulation of the PTEN-AKT-RAC1 Axis by G9a Is Critical for Tumor Growth in Alveolar Rhabdomyosarcoma.
Bhat AV; Palanichamy Kala M; Rao VK; Pignata L; Lim HJ; Suriyamurthy S; Chang KT; Lee VK; Guccione E; Taneja R
Cancer Res; 2019 May; 79(9):2232-2243. PubMed ID: 30833420
[TBL] [Abstract][Full Text] [Related]
2. EHMT1 promotes tumor progression and maintains stemness by regulating ALDH1A1 expression in alveolar rhabdomyosarcoma.
Nachiyappan A; Soon JLJ; Lim HJ; Lee VK; Taneja R
J Pathol; 2022 Mar; 256(3):349-362. PubMed ID: 34897678
[TBL] [Abstract][Full Text] [Related]
3. Histone Methyltransferases G9a/
Souza BK; Freire NH; Monteiro TS; Herlinger AL; Jaeger M; Dalmolin MGS; de Farias CB; Gregianin L; Brunetto AT; Brunetto AL; Thiele CJ; Roesler R
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894922
[TBL] [Abstract][Full Text] [Related]
4. Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer.
Thng DKH; Hooi L; Toh CCM; Lim JJ; Rajagopalan D; Syariff IQC; Tan ZM; Rashid MBMA; Zhou L; Kow AWC; Bonney GK; Goh BKP; Kam JH; Jha S; Dan YY; Chow PKH; Toh TB; Chow EK
Mol Oncol; 2023 Nov; 17(11):2275-2294. PubMed ID: 36896891
[TBL] [Abstract][Full Text] [Related]
5. G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status.
Agarwal P; Jackson SP
Cancer Lett; 2016 Oct; 380(2):467-475. PubMed ID: 27431310
[TBL] [Abstract][Full Text] [Related]
6. Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; de Miguel I; Ordoñez R; Garate L; Miranda E; Sáez E; Vilas-Zornoza A; Pineda-Lucena A; Estella A; Zhang F; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2021 Mar; 64(6):3392-3426. PubMed ID: 33661013
[TBL] [Abstract][Full Text] [Related]
7. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
[TBL] [Abstract][Full Text] [Related]
8. Gain-of-Function Genetic Alterations of G9a Drive Oncogenesis.
Kato S; Weng QY; Insco ML; Chen KY; Muralidhar S; Pozniak J; Diaz JMS; Drier Y; Nguyen N; Lo JA; van Rooijen E; Kemeny LV; Zhan Y; Feng Y; Silkworth W; Powell CT; Liau BB; Xiong Y; Jin J; Newton-Bishop J; Zon LI; Bernstein BE; Fisher DE
Cancer Discov; 2020 Jul; 10(7):980-997. PubMed ID: 32269030
[TBL] [Abstract][Full Text] [Related]
9. Non-canonical function of histone methyltransferase G9a in the translational regulation of chronic inflammation.
Muneer A; Wang L; Xie L; Zhang F; Wu B; Mei L; Lenarcic EM; Feng EH; Song J; Xiong Y; Yu X; Wang C; Jain K; Strahl BD; Cook JG; Wan YY; Moorman NJ; Song H; Jin J; Chen X
Cell Chem Biol; 2023 Dec; 30(12):1525-1541.e7. PubMed ID: 37858336
[TBL] [Abstract][Full Text] [Related]
10. A human Myogenin promoter modified to be highly active in alveolar rhabdomyosarcoma drives an effective suicide gene therapy.
Pruller J; Hofer I; Ganassi M; Heher P; Ma MT; Zammit PS
Cancer Gene Ther; 2021 May; 28(5):427-441. PubMed ID: 32973362
[TBL] [Abstract][Full Text] [Related]
11. Profiling genome-wide chromatin methylation with engineered posttranslation apparatus within living cells.
Wang R; Islam K; Liu Y; Zheng W; Tang H; Lailler N; Blum G; Deng H; Luo M
J Am Chem Soc; 2013 Jan; 135(3):1048-56. PubMed ID: 23244065
[TBL] [Abstract][Full Text] [Related]
12. The dopamine transporter antagonist vanoxerine inhibits G9a and suppresses cancer stem cell functions in colon tumors.
Bergin CJ; Zouggar A; Mendes da Silva A; Fenouil T; Haebe JR; Masibag AN; Agrawal G; Shah MS; Sandouka T; Tiberi M; Auer RC; Ardolino M; Benoit YD
Nat Cancer; 2024 Mar; 5(3):463-480. PubMed ID: 38351181
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic modifier G9a is involved in regulation of mouse tongue development.
Ideno H; Nakashima K; Komatsu K; Kimura H; Shinkai Y; Tachibana M; Nifuji A
J Oral Biosci; 2024 Mar; 66(1):35-40. PubMed ID: 38142940
[TBL] [Abstract][Full Text] [Related]
14. Molecular and functional anticancer effects of GLP/G9a inhibition by UNC0646 in MeWo melanoma cells.
Filiú-Braga LDC; Silva-Carvalho AÉ; Sousa MRR; Carvalho JL; Saldanha-Araujo F
Heliyon; 2024 Mar; 10(5):e27085. PubMed ID: 38434406
[TBL] [Abstract][Full Text] [Related]
15. PTEN isoforms with dual and opposing function.
Taylor J; Abdel-Wahab O
Nat Cell Biol; 2019 Nov; 21(11):1306-1308. PubMed ID: 31685989
[TBL] [Abstract][Full Text] [Related]
16. EHMT2 promotes tumorigenesis in
Li Y; Zhu T; Yang J; Zhang Q; Xu S; Ge S; Jia R; Zhang J; Fan X
Acta Pharm Sin B; 2024 Mar; 14(3):1187-1203. PubMed ID: 38486999
[TBL] [Abstract][Full Text] [Related]
17. BRD4 isoforms have distinct roles in tumour progression and metastasis in rhabdomyosarcoma.
Das D; Leung JY; Balamurugan S; Tergaonkar V; Loh AHP; Chiang CM; Taneja R
EMBO Rep; 2024 Feb; 25(2):832-852. PubMed ID: 38191874
[TBL] [Abstract][Full Text] [Related]
18. Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in Rhabdomyosarcoma.
Pomella S; Danielli SG; Alaggio R; Breunis WB; Hamed E; Selfe J; Wachtel M; Walters ZS; Schäfer BW; Rota R; Shipley JM; Hettmer S
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345159
[TBL] [Abstract][Full Text] [Related]
19. Cancer resistance via the downregulation of the tumor suppressors
Moghaddam M; Vivarelli S; Falzone L; Libra M; Bonavida B
Explor Target Antitumor Ther; 2023; 4(2):170-207. PubMed ID: 37205308
[TBL] [Abstract][Full Text] [Related]
20. A20 interacts with mTORC2 to inhibit the mTORC2/Akt/Rac1 signaling axis in hepatocellular carcinoma cells.
Wang X; Xiao Y; Dong Y; Wang Z; Yi J; Wang J; Wang X; Zhou H; Zhang L; Shi Y
Cancer Gene Ther; 2023 Mar; 30(3):424-436. PubMed ID: 36411371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
